Procena znanja i stavova farmaceuta o retkim bolestima i lekovima za retke bolesti by Krajnović, Dušanka et al.
www.medfak.ni.ac.rs/amm 23  
Original article                                                                        UDC: 615.15:[616:615.2 
                                                                                                    doi:10.5633/amm.2013.0204 
 
 
 
 
 
EVALUATION OF PHARMACISTS’ KNOWLEDGE AND ATTITUDES 
REGARDING RARE DISEASES AND ORPHAN DRUGS 
 
Dušanka Krajnović1,2, Jasmina Arsić3, Dragana Jocić1,4, Andrijana Milošević Georgiev1, 
Ljiljana Tasić1, Valentina Marinković1 
 
 
Rare diseases (RD) are very heterogenic group of disorders affecting less than 5 out 
of 10.000 people in the European Union (EU), at the same time putting them in danger 
or disabling them chronically. It is estimated that only in Serbia almost half a million 
people suffer from some RD. In spite of rarity, they represent an important medical and 
social problem. 
The aims of this pilot project were to evaluate the pharmacists` general knowledge 
and specific knowledge regarding RD, regulatory requirements and availability of drugs 
for the RD in the Republic of Serbia as well as pharmacists` attitudes and understanding 
of the health public importance of RD and drugs` availability. The prospective cross- 
sectional KAP study was conducted during 2012, on a convenient sample of the 
community pharmacists from the territory of the Niš branch of Pharmaceutical Chamber 
of Serbia. The questionnaire was fully completed by 139 pharmacists; 89.2% were 
females with mean age of 43.4±9.1 years. More than half of the respondents (66.9%) 
knew that there was no Register of RD in Serbia, but did not know the estimated 
percentage of the EU population suffering and the prevalence of RD (67%, 51.8%, 
respectively). Insufficient information about the problem points to insecurity in basic 
epidemiology and regulatory knowledge. The majority of the respondents supported the 
establishment of the regulatory instruments for the promotion of the research and 
development of the orphan drugs for RD. Acta Medica Medianae 2013;52(2):23-32. 
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 Introduction 
  
 Rare diseases are an important medical and 
social problem which many health systems in 
both developed and undeveloped countries all 
over the world are facing (1). According to the 
definition proposed by the EU Committee of 
Experts on Rare Diseases, these are diseases 
that are detrimental to human health or disable it 
chronically with an occurrence of at least 1:2000, 
i.e. affecting less than 5 out of 10.000 people. 
National regulatory body defines the criteria for 
“rareness” of each disease, based upon its 
prevalence. Pursuant to the definition of the U.S. 
Food and Drug Administration (FDA), these are 
diseases with the prevalence of 1:1250 people 
(2). However, many rare diseases (>3500) occur 
only among few people all over the world (3). 
Differences between the prevalence of diseases 
and the population size make differences in the 
number of all rare diseases’ patients as well as 
the number of specific rare diseases’ patients in 
one country or region.  
 Rare diseases comprise a very hetero-
geneous group of disorders with little in common 
except the fact that they are rare. About 6-8.000 
types of rare diseases have been listed in the 
world among which 80% can be attributed to 
genetic heritage, whereas the remaining ones are 
either contagious or autoimmune (4). According 
to the EU Committee of Experts for Rare 
Diseases, these illnesses affect about 6-8% of 
people in the European Union (about 30 million 
out 50 million people). A common characteristic 
is that these diseases are chronic and degene-
rative with the first symptoms occurring already 
at birth or during early childhood (with 50% of 
cases) and are often treated for entire lifetime if 
a known treatment can be applied. Further 
characteristics indicate that the most common 
consequence of rare diseases is permanent 
disability, loss of patient autonomy and decreased 
quality of life among affected patients (4). Yet, 
more than 50% of rare diseases may develop 
only at mature age, such as Huntington’s, Fabry 
and Crohn’s. 
 Orphan drugs are products used for diagnosis, 
prevention and treatment of rare diseases and as 
such they are necessary for the need of public 
health although their development has not been 
supported by the pharmaceutical industry due to 
economic reasons. From the historical point of 
view, health systems have not been dealing 
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much with the needs of patients suffering from 
rare diseases but have rather been directed to 
the most common diseases. Hence, the name of 
drugs used in treatment of these diseases was 
orphan drugs. The fact is that about 30% of all 
drugs labelled as “orphan” are classified as 
innovative drugs (3). 
 For many diseases there is no treatment 
and if there is some, provided it has started on 
time and that it is available, there may be a good 
prognosis that most of the affected people have   
normal life. The diagnosis and the treatment of 
those affected by rare diseases are difficult. A 
further difficulty can be identified as insufficient 
awareness and knowledge about these diseases 
among laymen and professionals. That is why 
rare diseases are also labelled as “orphans” (they 
have been neglected by professionals, researchers 
and the general public) (5). 
 Health policy creators and regulators do not 
recognize rare diseases as a public health problem 
because health resources and health technology 
are limited and directed towards the most 
common diseases most people in the world suffer 
from. This creates an even greater gap between 
the equity and accessibility of treatment to 
patients with rare disease and those with common 
diseases, because you should not expect mutual 
understanding among patients for treatment of 
others at the expense of other treatment. The 
pharmaceutical industry has no interest in the 
research and development of new drugs in this 
area, whereas health services, i.e. professionals 
involved in diagnosing and treating patients show 
little interest and inadequate understanding, 
especially since they have little knowledge of rare 
diseases. Rare diseases became a prevailing 
problem in the area of public health during the 
nineties in the previous century when the World 
Health Organization pointed out the need that 
this group of patients should be taken care of. 
Therefore, the interest of researchers, practi-
tioners and the industry has been provoked (7, 8).  
 From the point of view of people in the health 
industry, it is very important to have adequate 
knowledge, training and valid information at hand 
so as to inform the general public in an appro-
priate way. For instance, 1,300 rare diseases have 
been described properly whereas other rare 
diseases have no adequate medical description. 
Doctors and pharmacists are not trained enough 
and they lack experience in the treatment of rare 
diseases. 
 A particularly sensitive issue in this area is 
the availability of medical services. The prices for 
orphan drugs are usually high. A comparative 
research conducted in 15 countries of the 
European Union showed that the availability and 
price clearly differ in each of these countries (9). 
Since the costs for orphan drugs are the same in 
both developed and undeveloped countries, it is 
very difficult for patients in undeveloped countries 
to afford such treatments. Due to the fact that 
the prices of some innovative orphan drugs, 
which can be successfully used for treatment of a 
few diseases (i.e. Gaucher's disease, Morbus 
Fabry), are very high, and that the state can 
burden the medical funds, these drugs are 
usually not registered by pharmaceutical industry 
but frequently donated to charity for the most 
difficult cases until the state accepts participation 
in the financing of treatment of patients (6). In 
order to make services available, a particular 
infrastructure is needed to provide medical and 
psychosocial protection. An adequate allocation of 
resources may considerably decrease the burden of 
the disease for many patients. A European 
research focused on diagnosing and accessibility 
of services within the health sector and social 
services in 20 European countries has shown that 
40% of rare diseases were first diagnosed wrongly, 
which brought about severe consequences including 
inadequate and expensive medical interventions, 
such as surgery and psychological treatment, 
while 59% of the respondents said they had to 
either cut down on their professional activities or 
completely stop practising them because of their 
illness or because they had to take care of a 
family member with  a rare disease (10). 
 From the point of view of health policies, 
regulations and legislation, orphan drugs differ 
from country to country so that authorizing sales 
and availability through health security is being 
regulated in different ways.  
 United States (Orphan Drug Act of 1983), 
Japan (1985) and Australia (1997) are far ahead   
with respect to regulations compared to the EU 
(2000). In both regions of the world, there is the 
same two-step system for the approval of 
regulatory authorities to market, by giving 
"marketing authorization for “orphan” drug (MA) 
or “orphan designation" and a clear incentive to 
industry research and development of this group 
of drugs (eg. fee reduction and exemption from 
various taxes, faster simplification of procedures 
for obtaining a medicinal product, obtaining an 
extension of the exclusivity of the product in the 
market) (6, 11). By the end of 2006, the FDA 
issued 1713 “designations  for orphan drugs” and 
304 MA, whereas in the EU 443 “designations  for 
orphan drugs” were issued and 32 orphan drugs 
were licensed in the same period (11, 12). A 
growing interest in the research and development 
of orphan drugs has become evident as a result 
of the development of biotechnological drugs.  
 In the Republic of Serbia, among 1969 
registered drugs with proprietary name from 
2012-drug list of the Health Insurance Fund  
(Republicki fond za zdravstveno osiguranje – 
RFZO) 28 INN drugs from the Orphanet base 
were listed, specific for certain rare diseases 
(13). Interest in orphan drugs and rare diseases 
has grown since 2000. The National Organization 
for Rare Diseases in Serbia (Nacionalna organi-
zacija za retke bolesti Srbije – NORBS) was 
founded in 2010 and according to their data, 
there are between 480,000 and 640,000 people 
in Serbia suffering from some rare disease (10); 
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however, despite such a huge number of patients, 
there is still no reference to national centre for 
the registration of rare diseases, there is no 
register of drugs for rare diseases nor is there a 
codebook of rare diseases.   
 The Regulation of Import Conditions for 
Drugs and Medical Equipment without a licence 
for Sales (2008) includes a list of 258 rare 
diseases in the Republic of Serbia (14). Pursuant 
to the Law of Alterations and Amendments of the 
Health Care Law (2011), patients suffering from 
some rare disease belong to a particularly 
sensitive category, classified into the group of 
patients exposed to a higher risk of illnesses 
potentially covered by insurance (15). Implemen-
tation, improvement and development of activities 
and evaluation programmes of health promotion, 
primary, secondary and tertiary prevention as 
well as the control of rare diseases were recognized 
by the Law of Public Health (Official gazette Sl. 
Glasnik RS, issue 72/2009) as a health activity of 
public interest (15). The current changes in the 
Health Care Law and Health Insurance in 2011 
initiated the creation of the fund within the 
Ministry of Health of the Republic of Serbia to 
cover rare diseases. Most patients suffering from 
rare diseases in Serbia have not been recognized 
in the system of health insurance. They are facing 
stigma and high prices of drugs. 
 
 Aims 
  
 1. The evaluation of knowledge of pharma-
cists regarding rare diseases, regulations of drugs 
needed for the treatment of rare diseases and 
their availability in the Republic of Serbia.   
 2. The evaluation of the attitudes of pharma-
cists and their understanding of the public impor-
tance of rare diseases and the availability of treat-
ment for patients suffering from rare diseases. 
 
Methods 
 
 The study represents a pilot project conducted 
with an appropriate sample of pharmacists. The 
research was realized in pharmacies at the primary 
level of health protection during the year 2012. 
The prospective cross-sectional study included 
the population of licensed pharmacists on the 
territory of the Niš branch of FKS (mermbers from 
the Kosovo and Metohia were not available). The 
Niš branch with Kosovo and Metohia includes the 
following districts: Nišavski, Zaječarski, Borski, 
Rasinski, Pirotski, Toplički, Pčinjski, Jablanički, 
Kosovski, Kosovsko-pomoravski, Kosovsko-mitro-
vački, Prizrenski and Pećki. It comprises 770 
active members from all parts except members 
from Kosovo and Metohija (17). For the data 
collection, a specially designed instrument was 
used according to the aims of the research. A 
questionnaire was designed by means of which the 
socio-demographic characteristics of the respon-
dents could be collected. At the same time, their 
knowledge could be assessed and their attitudes 
could be estimated. 
 The questionnaire consisted of 11 multiple 
choice questions, two scales for the evaluation of 
attitudes and two problem-solving tasks by 
means of which the participants could express 
their attitudes to the importance of rare diseases 
as far as public health was concerned. A national 
study was planned and an improved version of 
this questionnaire was supposed to be used. The 
statistic computer processing programme used 
was SPSS (SPSS 18.0 for Windows, Inc., Chicago, 
IL, USA). During the data processing, the methods 
of descriptive statistics and correlation analysis 
were used.  
 
 Results 
 
 93.4% of respondents (170/182 pharma-
cists) completed and returned the questionnaire 
but the data basis for the analysis included only 
139 completed questionnaires. The description of 
the respondents according to gender, age and 
level of education as well as work experience in a 
pharmacy is presented in Table 1. 
 A little more than half of the polled 
pharmacists used only one source of information 
while the remaining information regarding rare 
diseases was collected from various sources 
(Figure 1).  
 The respondent’s opinions regarding the 
frequency of rare diseases in respect to a certain 
sample of population suffering from rare diseases 
are divided. Almost half of the respondents 
believes that rare diseases have an occurrence of 
1 per 2.000 people, one third of them is aware of 
the situation regarding rare diseases (48.2%, 
33.0% respectively), while the remaining number 
of respondents did not provide a correct answer, 
which is presented in Figure 2. Differences between 
the respondents knowledge about regulatory issues 
concerning rare diseases and orphan drugs are 
presented in Figure 3. 
 The respondents believe it is necessary and 
possible to have a regulatory instrument for 
further research of rare diseases. The results 
indicate that almost all respondents (91.4%) 
agree that it is necessary to have a regulatory 
instrument (law, regulation or agreement) which 
would support further research and development 
of drugs for rare diseases. However, when asked 
whether such regulatory instrument could be 
implemented, only 64.7% believed that such 
instruments could be implemented while one 
third among them (29.5%) was not sure about it.  
 The evaluation of the respondents’ attitudes 
regarding the awareness of the importance of 
rare diseases in the public health sector, the 
availability of drugs and the encouragement for 
research and development of drugs, was 
evaluated by means of a five-level scale ranging 
from “very important” to “unimportant” and the 
results are presented in Table 2. 
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 Only a very small percentage of respondents 
in the entire sample, 0.7 – 2.9% did not have any 
opinion regarding some of the attitudes. 
 The lack of public awareness in the society 
regarding rare diseases is in correlation with the 
lack of priorities in managing the needs of the 
people suffering from rare diseases in the public 
financing sector (r=0.526; p<0.01) and the attitude 
that the ones suffering from rare diseases may 
have the right to free treatment with some drugs 
even if the treatment itself is expensive (r=0.389; 
p<0.01). 
 The correlation analysis provided the rela-
tionship between certain variables based on the 
scale used, such as difficult economic situation of 
the family/ guardian in correlation with the lack 
of public awareness about rare diseases (r=0.535; 
p<0.01); the lack of access to existing efficient 
treatment because drugs have not been regi-
stered in the country (r=0.670; p<0.01); the lack 
of priorities in managing the needs of patients 
within the public financing sector (r=0.401; p<0.01); 
the difficulties in the area of research of specific 
diseases (unknown aetiology, lack of research 
material) (r=0.412; p<0.01; no investments in 
furthering research and development of drugs 
needed for rare diseases (r=0.376; p<0.01); no 
drugs for rare diseases (r=0.343; p<0.01); patients 
suffering from rare diseases may have the right 
to free treatment with some drugs even if the 
treatment itself is expensive (r=0.381; p<0.01).  
 The lack of access to existing efficient treat-
ment, because drugs are not registered in the 
country, has been correlated with the following 
variables: the lack of priorities in managing the 
needs of people suffering from a rare disease in 
the public financing sector (r=428; p<0.01) and 
the lack of drugs for the treatment of rare 
diseases (r=0.411; p<0.01). 
 The distribution of rare diseases has been 
correlated with the difficulties encountered in the 
research of specific diseases (unknown aetiology, 
lack of research material (r=0.402; p<0.01) and 
the load of the disease itself (r=0.646; p<0.01). 
 
Table 1. Basic demographic characteristics of respondents 
 
Characteristic Value p 
Total number of respondents 139  
Age (years) x =43.4±9.1 p<0.01 
Age range 24-72 p<0.01 
Male 15 (10.8%) p<0.01 
Female 124 (89.2%) p<0.01 
Post-graduating training 12 (8.6%) p<0.01 
Work experience in pharmacy x =16.7±9.8 p<0.01 
 
 
 
Figure 1. Number of used sources of information regarding RD 
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Figure 2. Knowledge regarding the total population suffering from RD and the prevalence of RD in EU 
 
 
 
 
  
Figure 3. Level of knowledge among the respondents regarding orphan drugs and legislation about RD 
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Table 2. Pharmacists’ attitudes regarding the importance of RD in the public health sector and the availability of 
treatment to patients suffering from RD 
 
Items in the Questionnaire to 
assess pharmacists attitudes 
stavke u skali) 
Very 
significant 
(%) 
Mostly 
significant 
(%) 
Significant 
(%) 
Little 
significant 
(%) 
Insignificant 
(%) 
No 
judgment 
(%) 
Lack of public awareness of rare 
diseases 
51.8 18 27.3 1.4 1.4 0 
Threatened  economic situation 
of the family / carers 
71.2 14.4 12.9 1.4 0 0 
Lack of access to existing 
effective treatment 
69.8 18 11.5 0 0.7 0 
No access to existing effective 
treatment 
64 22.3 10.1 3.6 0 0 
Prevalence of diseases 36.7 25.2 28.1 7.2 2.2 0.7 
Burden of diseases 50.4 20.9 18 10.8 0 0 
Diseases/ specific research 
difficultes (unknow etiology, lack 
of research material) 
54.7 23 18.7 2.2 0.7 0.7 
Lack of health needs driven 
priority setting in public funding 
61.2 20.9 15.1 1.4 0.7 0.7 
No drugs for rare diseases 61.2 25.2 10.1 2.2 0.7 0.7 
Ineffective drugs for rare 
diseases 
44.6 26.6 20.9 2.9 2.2 2.9 
No adequate health delivery 
infrastructure and human 
resources in developing countries 
51.8 25.9 18.7 2.2 1.4 0 
Inadequate health delivery 
infrastructure and human 
resources in developing countries 
54 25.2 19.4 0.7 0 0.7 
No incentives for investment into 
research and development for 
rare diseases 
54.7 28.8 13.7 0 1.4 1.4 
Inadequate incentives for 
investment into research and 
development for rare diseases 
54 24.5 17.3 1.4 0.7 2.2 
No investment in research and 
development of drugs for rare 
diseases 
57.6 24.5 14.4 0.7 0.7 2.2 
Inadequate investment in 
research and development of 
drugs for rare diseases 
57.6 23 13.7 1.4 1.4 2.9 
Poverty as an important 
determinant of health 
64.7 22.3 8.6 2.9 1.4 0 
Poverty as a cause of the lack of 
treatment (no drugs in poor 
countries or drugs are not 
available, insufficient investment 
in research and development) 
66.2 20.1 10.1 1.4 2.2 0 
 p <0,01 
 
 Discussion 
  
 During the last few years, the world has 
witnessed an increase in interest of the health 
authorities as well as the public regarding rare 
diseases and drugs needed for their treatment. 
The number of studies related to the general 
knowledge of healthcare employees and the 
evaluation of their attitudes is limited whereas 
the results of most of this research are not homo-
geneous and there are considerable differences 
between the groups included in the research. For 
the purpose of this research conducted among 
pharmacists, two European and one national 
study was used: one was conducted among the 
general public (17) and the other among health-
care employees, which included pharmacists from 
the pharmaceutical industry (Delphi) (18) and the 
study conducted by Mitev including healthcare 
employees in Bulgaria (19). 
 A good response of respondents in this 
research may indicate both an interest of health-
care employees in this area as well as the fact 
that the data were collected with an anonymous 
questionnaire.  
 Almost half of the surveyed pharmacists in 
our research (48.2%) knew about the correct 
prevalence of rare diseases, which is a much 
higher percentage in comparison to the results 
indicated in the Bulgarian study with doctors 
(19.82%) (19). 
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 This research showed that 33% of the 
respondents provided a correct response to the 
answer regarding the range of the European 
population suffering from rare diseases, while a 
rather lower number of respondents (6.9%) 
supplied a correct answer to that question in the 
Bulgarian study conducted by Mitev (18). The 
differences noticed about the knowledge in both 
studies can be attributed to the different 
instruments used because of the Bulgarian study, 
Mitev used a telephone interview, which implies 
less time for the respondents to check some 
other sources of information (18). There are huge 
differences in the knowledge among the 
respondents in the Serbian research regarding 
regulating aspects of rare diseases and drugs 
used for the treatment in the Republic of Serbia 
because pharmacists supplied correct answers to 
6 questions with answers ranging from 15.8% to 
66.9%. The lowest level of knowledge was shown 
by pharmacists with the questions not directly 
related to their everyday work, such as the 
registration of drugs used in the treatment of 
rare diseases and the Law of Public Health 
(15.8%, 37.4% respectively). When answering 
the questions related to their everyday work 
activities, the pharmacists provided mainly correct 
answers. A large percentage of respondents knew 
about “the conditional licence for the registration 
of drugs used in the treatment of rare diseases” 
(64.7%); they knew that there is no register of 
rare diseases (66.9%), the possibility of the sick 
to pursue their insurance in our country (54%) as 
well that there is no national Orphan drugs’ Law 
(51.8%). The available literature does not provide 
any information regarding the knowledge of 
regulatory laws among healthcare employees so 
that such information is invaluable. 
 In the second part of this research, which 
deals with the attitudes of pharmacists about the 
importance of public health importance of rare 
diseases and treatment availability, the result   of 
two studies, one conducted among the general 
population (17) and the Delphi research conducted 
among healthcare employees including pharma-
cists from the pharmaceutical industry (18) can 
be compared.   
 Almost all the respondents in both the 
Serbian and the Delphi research agree that it is 
necessary to have regulatory instruments (law, 
regulations or agreements) so that research and 
development of rare diseases could be furthered. 
At the same time, they are careful when 
predicting the feasibility of implementing such 
instruments (18). Such carefulness expressed by 
healthcare employees can be interpreted based 
on their attitude regarding awareness and the 
long-term effects such changes would ask of 
regulatory bodies within the current legislation 
while related to the furthering of research and 
development of financing sources for this group 
of drugs. Almost the same number of respon-
dents in this and a similar research conducted in 
Europe in 2010 agrees upon the attitude that 
public awareness of rare diseases is still missing 
(17). Providing health support to people suffering 
from rare diseases and a complete compensation 
of costs for some drugs, even if they are 
expensive, was recognized as an an important 
measure (17). Agreement with the idea that 
drugs for these diseases are completely refunded 
is present in both this and the European 
research. As far as the attitudes regarding the 
lack of priorities in managing the need in the 
public health financing sector are concerned, it 
was established that it was one of the most 
important influence on the treatment of the sick. 
Both researches agreed on this issue but some 
differences between the Serbian and the 
European studies could be established in the 
attitudes among respondents regarding different 
regions in Europe. 
 This research showed that 9 out of 10 
pharmacists (97.2%) identifie the lack of priorities in 
the management of the needs of people suffering 
from rare diseases as important within the public 
health financing sector, which may be interpreted 
as a high level of awareness among the respon-
dents. Similar attitudes among healthcare employees 
were not measured in the European studies but 
an interesting fact in the general public could be 
identified – 39% of the respondents in the 
European study believe that the priority in their 
countries regarding health protection can be 
attributed to other health problems and not rare 
diseases. This points to the fact that broader and 
further research is needed in the population of 
healthcare employees who could influence the 
decision making within healthcare policies by 
means of their higher awareness and attitudes 
(17).  
 The attitudes of respondents regarding the 
treatment of rare diseases as far as existing 
drugs or their unavailability is concerned, since 
they are not reregistered, were evaluated in a 
similar way in this research and the research 
conducted among the population of healthcare 
employees (18). In the Delphi research, 41.0% 
of respondents believed that the lack of or 
difficult accessibility to existing efficient treatment 
is important while the Serbian research showed 
that 69.8% of respondents believed that the lack 
of accessibility to existing efficient treatment is 
very important. A total of 64% of the respon-
dents in the Serbian research believed that the 
lack of accessibility to existing efficient treatment 
is very important. 
 The attitudes of the respondents regarding 
the treatment of rare diseases related to the lack 
of drugs or their unavailability as they are not 
registered were evaluated in a similar way in this 
research and the Delphi research. While 58.3% of 
respondents in the Delphi research believed that 
the unavailability of treatment due to a drug 
missing or not being efficient was important, the 
Serbian research showed that among the pharma-
cists, 61.2% believed the missing drug in the 
treatment of rare diseases was very important 
and 44.6% of the respondents believed the 
unavailability of treatment was very important (18). 
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 The lack of investment or inadequate 
investment in the furthering of research and 
development of drugs of rare diseases was 
considered important by half of the respondents 
in the Serbian research and by almost half of the 
respondents (45.2%) in the Delphi research (18). 
 Poverty as a very important determinant of 
health and the cause of missing treatment, in the 
Serbian research, was attributed to a high level 
of importance, a slightly higher level than in the 
Delphi research. The reason for this type of 
attitude in the Serbian research may be found in 
the difficult economic situation and general 
poverty in Serbia (20).  
 Inadequate distribution of infrastructure 
and resources in the health sector in undeveloped 
countries is of huge importance according to half 
of the pharmacists in the Serbian research and 
almost the same number of respondents agrees 
in the Delphi research (18). Apart from that, the 
lack of drugs for the treatment of rare diseases in 
the Serbian research was rated as highly 
important (very important by 61.2%, mainly 
important by 25.2%, and important by 10.1%). 
For 30% of respondents in the Delphi research, 
the lack of drugs for rare diseases is very 
important. 58.3% believe that this issue is 
important because of the lack of treatment of 
rare diseases (18). 
 Similarly, the respondents in the Serbian 
research chose the issue of financing as very 
important. The lack of an adequate distribution of 
infrastructure in the health sector as well as the 
professional workforce in undeveloped countries 
was considered important by 51.8%, while 
25.9% in the Serbian research rated this as 
mainly important. In the similar Delphi research, 
45.9% rated this issue as very important and 
41.0% as important (18).   
 The issue of financing was a high priority in 
both researches. The lack of investment in the 
research and development of drugs for rare 
diseases, in the Serbian research was rated as 
very important by 57.6%, mainly important by 
24.5% and important by 14.4%. In the Delphi 
research, 48.4% rated the lack of investment in 
the research and development of drugs for rare 
diseases as very important, 48.4% agrees with 
this and 37.1% think this issue is important (18). 
 The similar attitudes in the Serbian and the 
Delphi research indicated the complexity of these 
issues and the need to support a strategy which 
would raise awareness, decrease poverty, include 
rare diseases into the priorities of research and 
development, improve and sustain financing, 
promote health and the research infrastructure in 
all countries. Most respondents in the Serbian 
research supported the implementation of regu-
latory instruments for furthering the research and 
development of drugs for rare diseases. One of 
the key issues is the national responsibility for 
financing research and development, which is 
considered necessary by the most respondents in 
the Serbian study. That is why it might be of 
interest to spread and direct research in the area 
of determining the measures, which could contri-
bute to future instruments needed for promoting 
the research and development of rare diseases’ 
treatment. 
  
 Conclusions 
  
 The general knowledge of pharmacists 
regarding rare diseases, regulations and drugs 
for the treatment of rare diseases in public 
pharmacies on the territory of the Niš branch FKS 
is in accordance with the knowledge about rare 
diseases identified in European studies. The lack 
of knowledge among pharmacists regarding the 
problem of rare diseases indicates a high level of 
insecurity when it comes to knowing about the 
basic regulation demands related to rare diseases 
and the drugs for their treatment in Serbia. 
However, based on the answers to the questions 
regarding pharmacists’ attitudes related to rare 
diseases being a public health problem, a general 
attitude of interest in this problem is obvious. 
The similarity between the responses in both the 
Serbian and the European research indicates the 
complexity of these issues and the need to 
support a strategy which would raise awareness, 
decrease poverty, and include rare diseases in 
the priorities of research and development of 
infrastructure in all countries. The encouragement 
to develop effective treatment of people suffering 
from rare diseases may be found in the non-
economic social values, i.e. the wish to develop a 
fair approach to the treatment of the sick. The 
basic message conveyed by this research as far 
as the creators of the healthcare policies in the 
Republic of Serbia are concerned might be that 
among the pharmacists in public pharmacies on 
the territory of the Niš branch FKS, a widely 
spread readiness could be noticed. This readiness 
is related to the wish to provide support to 
people suffering from rare diseases, within the 
range of professional possibilities. Furthermore, 
the readiness is related to the need for further 
and broader research, including pharmacies in 
certain campaigns or determining days for rare 
diseases as well as raising the level of general 
knowledge on rare diseases, regulations and the 
availability of orphan drugs. 
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PROCENA ZNANJA I STAVOVA FARMACEUTA O RETKIM BOLESTIMA I 
LEKOVIMA ZA RETKE BOLESTI  
 
Dušanka Krajnović, Jasmina Arsić, Dragana Jocić, Andrijana Milošević Georgiev, 
Ljiljana Tasić, Valentina Marinković 
 
 
Retke bolesti su heterogena grupa životno ugrožavajućih ili hronično onespo-
sobljavajućih oboljenja, koja se prema kriterijumima evropske regulative javljaju sa 
učestalošću od najmanje jednog prema 2000 stanovnika. Uprkos tome što su retke u 
populaciji, one predstavljaju važan medicinski i socijalni problem sa kojim se susreću 
zdravstveni sistemi širom sveta. Procene su da samo u Republici Srbiji od retkih bolesti 
boluje skoro pola miliona ljudi. 
Ciljevi ovog pilot projekta bili su da se procene opšta i specifična znanja farmaceuta o 
retkim bolestima, regulativi u vezi sa lekovima za lečenje retkih bolesti i njihovoj 
dostupnosti u Republici Srbiji i utvrde stavovi farmaceuta o značaju retkih bolesti i 
dostupnosti terapije za bolesnike.  
Prospektivna studija preseka obuhvatila je farmaceute koji rade na teritoriji niškog 
ogranka Farmaceutske komore Srbije. Prikupljanje podataka obavljeno je tokom 2012. 
godine pomoću strukturiranog, anonimnog upitnika, posebno konstruisanog prema 
ciljevima istraživanja, a za obradu podataka korišćene su metode deskriptivne statistike i 
korelaciona analiza.  
Upitnik je potpuno popunilo 139 farmaceuta, pretežno ženskog pola (89,2%), 
prosečne starosti 43,4 ±9.1 godine. Više od polovine ispitanih farmaceuta (67%) ne zna da 
6-8% populacije u EU boluje od neke retke bolesti, dok 51,8%  smatra, što je pogrešno, da 
je prevalenca u Evropi manja od 5 na 10 000 ljudi. Većina ispitanika (66,9%) zna da u 
Srbiji ne postoji Registar retkih bolesti. Nedovoljna informisanost farmaceuta ukazuje na 
nesigurnost u poznavanju osnovnih regulatornih zahteva u vezi sa retkim bolestima i 
lekovima za njihovo lečenje. Većina ispitanika se u svojim stavovima zalagala za 
uspostavljanje regulatornih instrumenata za promovisanje istraživanja i razvoja lekova za 
retke bolesti. Acta Medica Medianae 2013;52(2):23-32. 
 
Ključne reči: retke bolesti, orphan lekovi, regulativa, farmaceuti, KAP studija 
